Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer

Jonathan Chatzkel, Michael J. Schell, Jad Chahoud, Rohit Jain, Jingsong Zhang, Jennifer Swank, Steve Ludlow, Kristina Lombardi, Yesenia Lucas, Cortlin Croft, Jennifer Rembisz, Gigi Jameel, Mayer Fishman

PII: S1558-7673(22)00023-4
DOI: https://doi.org/10.1016/j.clgc.2022.01.010
Reference: CLGC 1702

To appear in: Clinical Genitourinary Cancer

Received date: Jan 4, 2022
Revised date: Jan 16, 2022
Accepted date: Jan 18, 2022

Please cite this article as: Jonathan Chatzkel, Michael J. Schell, Jad Chahoud, Rohit Jain, Jingsong Zhang, Jennifer Swank, Steve Ludlow, Kristina Lombardi, Yesenia Lucas, Cortlin Croft, Jennifer Rembisz, Gigi Jameel, Mayer Fishman, Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer, Clinical Genitourinary Cancer (2022), doi: https://doi.org/10.1016/j.clgc.2022.01.010

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Jonathan Chatzkel\textsuperscript{1}, Writing – original draft, Visualization, Investigation, Michael J. Schell\textsuperscript{2}, Methodology, Formal Analysis, Data Curation, Writing - review & editing, Visualization, Jad Chahoud\textsuperscript{3,4}, Writing – review & editing, Investigation, Rohit Jain\textsuperscript{3,4}, Writing – review & editing, Investigation, Jingsong Zhang\textsuperscript{3,4}, Writing – review & editing, Investigation, Jennifer Swank\textsuperscript{6}, Investigation, Yesenia Lucas\textsuperscript{3}, Investigation, Cortlin Croft\textsuperscript{3}, Investigation, Jennifer Rembisz\textsuperscript{3}, Investigation, Gigi Jameel\textsuperscript{3}, Investigation, Mayer Fishman\textsuperscript{4,6, FISHMAN@USF.EDU}, Conceptualization, Writing – review & editing, Visualization, Project Administration, Funding acquisition, Investigation

\textsuperscript{1}Division of Hematology and Oncology at the University of Florida College of Medicine, Gainesville, FL
\textsuperscript{2}H. Lee Moffitt Cancer Center, Department of Biostatistics and Bioinformatics, Tampa, FL
\textsuperscript{3}H. Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL
\textsuperscript{4}University of South Florida Morsani College of Medicine, Department of Internal Medicine, Tampa, FL
\textsuperscript{5}H. Lee Moffitt Cancer Center, Department of Pharmacy, Tampa, FL
\textsuperscript{6}Tampa General Hospital Cancer Institute, Tampa, FL

*Conflicts of Interest
MF has participated as paid advisory board member for Merck and for Clinigen in relation therapies for metastatic kidney cancer.

Abstract

Introduction: The ligation of the interleukin-2 (IL-2) receptor and immune checkpoint blockade may each alter lymphocytes, thereby inducing regression in various cancers. Single agent objective response rates of 14-25\% have been reported for usual schedule 14-dose-in-a-row IL-2 therapy of metastatic clear cell renal cancer (ccRCC), with a notable subset of responses being durable. Pembrolizumab yielded a 33\% response rate in patients with metastatic ccRCC.

Patients and Methods: This study addressed the safety and feasibility of the combination of IL-2 and pembrolizumab in the treatment of metastatic ccRCC. Subjects were treated with four nine-week blocks of therapy, receiving pembrolizumab every three weeks in all blocks and receiving four courses of 5-planned-doses high dose IL-2 in each of blocks two and three. Safety was monitored by a Pocock boundary of study suspension and re-evaluation if exceeding a 15\% dose limiting toxicity rate at $\alpha=0.05$. The Simon 2-stage design tested for an alternative hypothesis response rate of at least a 45\% versus a null hypothesis rate of less than 20\%, with $\alpha=0.10$ and 90\% power.

Results: No accrual suspension for safety was triggered. The objective response rate was 70\% (19/27, 95\% CI: 0.50-0.86). Nine patients responded after pembrolizumab alone and ten responded after the addition of IL-2. At a minimum follow-up of 23 months, nine of the responding patients had no disease progression requiring additional treatment.
Conclusion: The combination of 5-planned-dose-schedule high dose IL-2 and pembrolizumab is feasible, with a high response rate, justifying further exploration of this dual immune treatment of metastatic ccRCC.

Keywords
immunotherapy, pembrolizumab, Interleukin-2, Clear Cell Kidney Cancer

Introduction

Interleukin-2 (IL-2) has been utilized in the treatment of metastatic clear cell renal cancer (mCCRC) for decades. IL-2 binds to an activating receptor (CD25/CD122/CD132; IL-2Rαβγ) on lymphocytes and is associated with a single-agent response rate of approximately 15-20% and a durable complete response rate of 5-7%. Standard schedule 14-in-a-row high-dose IL-2 has shown increased efficacy when compared to subcutaneous IL-2 and interferon in the treatment of metastatic kidney cancer and is therefore a key consideration for this indication for those meeting selection criteria. Immune checkpoint inhibition has more recently impacted the treatment of kidney cancer. The interaction between PD-1 (CD279) and its ligand PD-L1 (B7-H1, CD274) serves to induce and maintain immune tolerance, and blocking this interaction is an effective treatment strategy in many malignancies, including mCCRC. For example, the PD-1 inhibitor nivolumab was shown to have a second-line response rate of 25%, and a single agent response rate of 36% has been reported for the PD-1 inhibitor pembrolizumab. CTLA-4 mediates immunosuppression by binding to CD80 and CD86, limiting the immunostimulatory interaction of CD28 with these ligands. The combination of the CTLA inhibitor ipilimumab and nivolumab showed an objective response rate of 42% in patients with intermediate and poor risk disease. Notably, 11% of patients had complete responses. In addition, there is increasing evidence that some responses are durable, with 28% of patients remaining free from progression at 30 months. Finally, VEGF-TKI (vascular endothelial growth factor receptor tyrosine kinase
inhibitor) based therapy has been widely utilized in the treatment of kidney cancer since the approval of sunitinib in 2006, and in 2019 the combination of the VEGF/TKI axitinib with the checkpoint inhibitors pembrolizumab or avelumab yielded response rates of 59.3% and 51.4%, respectively.\(^{14-17}\) More recently, the combination of cabozantinib and nivolumab has yielded a response rate of 55.7% and the combination of lenvatinib and pembrolizumab a response rate of 71.0%.\(^{18,19}\) As such, combinations with PD-1 therapy now represent a key component of the treatment landscape for mCCRC. Selection criteria for PD-1 combination treatment typically are less restrictive than the good risk concentration for standard high dose IL-2 monotherapy, with several PD-1/CTLA and PD-1/VEGF directed therapies having a higher relative impact in patients with intermediate risk or poor risk stratification.\(^{7,15,18,20}\)

Notably, the administration and side effect profiles of high-dose IL-2 and of anti-PD-1 therapy differ significantly. High-dose IL-2 requires a controlled setting with experienced staff and requires patients to have verified cardiac and pulmonary reserve. In addition, high-dose IL-2 has been associated with acute episodes of capillary leak syndrome as well as with significantly reduced neutrophil function.\(^{21}\) Pembrolizumab, in contrast, can be delivered in the outpatient setting, but is associated with risks of autoimmune adverse events which can have significant latency, and which can require prolonged treatment with immunosuppressive agents.\(^{22,23}\)

There may nonetheless be important synergies between IL-2 based therapy and checkpoint blockade. Cells which bear receptors for IL-2 stimulation may be modulated by checkpoint inhibition either directly or through other lymphocytes, and lymphocytes which are effectors of checkpoint inhibition may respond to IL-2.\(^{24-26}\) Interestingly, patients treated with anti-PD-1 therapy have been shown to undergo early intra-tumoral migration of lymphocytes, which would be then plausibly ripe for modulation via IL-2 therapy.\(^{27}\) In fact, there is evidence
that IL-2 may be efficacious following PD-1/L1 based therapy in patients with kidney cancer.\textsuperscript{28, 29} Pegylated formulations of IL-2 such as NKTR-214 (bempegaldesleukin) have also been a topic of recent clinical testing, and there is preliminary data to suggest that the combination of this treatment with anti-PD-1 therapy may have utility in several solid malignancies.\textsuperscript{21} Finally, the ability of IL-2 to induce decades-long durable responses in a minority of patients gives it particular appeal as a partner agent. As such, we undertook a phase II single arm, single institution study of the combination of pembrolizumab and 5-in-a-row schedule high-dose IL-2 in the treatment of mCCRC.

In summary some the rationale for the PD-1 treatment lead in part of the treatment included these: Mechanistically, there could be beneficial lymphocyte migration into the tumor\textsuperscript{27}; for toxicity evaluation, if there were events of rapid-onset auto-immune events as may occur in PD-1 therapy, those would not be confused with events unique to combination treatment; and for translational evaluation this would give the opportunity for study the changes of leukocyte phenotype from baseline to PD-1 exposure and then from PD-1 exposed to combination exposed, that is the particular IL-2 effect in this context.

**Materials and Methods**

The trial was conducted at the Moffitt Cancer Center (Tampa, FL) with the approval of the Moffitt institutional review board. The Moffitt Cancer Center has extensive expertise in the delivery of IL-2. Patients were eligible if they had metastatic kidney cancer with a clear cell component and had measurable disease as per RECIST 1.1.\textsuperscript{30} Patients were required to be relatively fit, with an ECOG performance status of 0 or 1.\textsuperscript{31} Patients also had to have acceptable laboratory parameters, including a creatinine of $\leq 1.5$ times the upper limit of normal (ULN) or an estimated GFR of $\geq 60$, a hemoglobin of $\geq 9$ g/dL, an absolute neutrophil count $\geq 1,500$/mcL,
platelets $\geq 100,000$, total bilirubin $\leq 1.5$ times ULN or direct bilirubin $\leq$ ULN, and an AST $\leq 2.5$ times ULN or $\leq 5$ times ULN in patients with liver metastases. Finally, patients were required to have acceptable exercise stress testing or thallium stress testing within 3 months of treatment initiation unless a cardiologist deemed this unnecessary, and acceptable pulmonary function testing within 3 months of treatment initiation. Patients were excluded if they had active brain metastases, active autoimmune disease requiring systemic treatment within the past two years, more than one systemic therapy in the prior year, any therapy with IL-2 within one year, or therapy with anti-PD-1 or anti-PD-L1 agents at any time.

The primary objective of the study was to determine the anti-tumor activity of the treatment, as defined by a hypothesis of an objective response rate of at least 45% among ever-treated patients, and to determine whether the treatment could be delivered safely, as evaluated via a sequential toxicity boundary method. Secondary objectives included: 1) assessing the objective response rate for patients receiving at least four doses of pembrolizumab with one dose of IL-2, 2) assessing the objective response rate for patients receiving at least twenty doses of IL-2 with at least six doses of pembrolizumab (half the planned doses), and 3) determining if the objective response rate and/or survival at one year were not more than 20% lower than that of matched controls identified in the PROCLAIM database of IL-2 treated patients. Exploratory objectives included an assessment of several correlative markers, which will be reported separately.

Patients received pembrolizumab at the standard dose and frequency of 200 mg every 3 weeks, with a total of 12 doses provided, organized as four blocks of 3 doses. Following the first and second doses of pembrolizumab in the second and third blocks of treatment (as detailed in Figure 1), patients underwent two weekly courses of treatment with 5-in-a row high-dose IL-2
(with each course consisting of 600,000 IU/kg of IL-2 given every eight hours for up to 5 doses as tolerated). As such, patients were planned to receive 20 doses of IL-2 in the second and third 9-week blocks of treatment. Missed doses, for either medication, were not made up. Of note, this five-in-a-row dose schedule has been shown to have relatively uniform dose delivery while maintaining a similar toxicity profile and response rates to the traditional 14-in-a-row schedule.\(^{33}\)

Patients underwent CT imaging at baseline, every nine weeks during active treatment, and then every 2-3 months for 24 months.

A Simon two-stage minimax design, with a 10\% type I (alpha) error and a 90\% power, was utilized to test the null hypothesis of an objective response rate of at most 20\%, versus an alternative hypothesis objective response rate of at least 45\%.\(^{34}\) The 95\% confidence interval for the response rate was calculated using the Wilson score methods.\(^{35}\) Patients were considered evaluable for the efficacy analysis if they received at least one dose of pembrolizumab and one dose of IL-2. In the initial stage, 15 patients were to be evaluated, and if 3 or fewer responded, the trial accrual was to be terminated. In the second stage, an additional 9 patients were to be evaluated, and if at least 8 patients responded between the two stages, the null hypothesis would be rejected. Up to 26 patients were to be enrolled, to allow for patients who were not evaluable.

A sequential boundary method was utilized to monitor dose-limiting toxicities.\(^{32}\) This accommodated an open-ended follow-up period for the earlier subjects while the latter were just starting. This was accomplished with a Pocock-type stopping boundary, yielding a probability of crossing the boundary of at most 0.05 when the rate of dose limiting toxicities was at the acceptable limit of 15\%. Patients who had received at least one dose of pembrolizumab were included in the safety evaluation.
Results

27 patients enrolled in the study, of whom 26 received any study treatment. Baseline demographics and disease characteristics were as expected for a group of patients with advanced kidney cancer who were nonetheless fit enough to undergo a relatively intensive treatment protocol (Table 1). IMDC risk category was favorable for 37%, intermediate for 59%, and poor for 4%. The median age was 60, and 37% of patients were at least 65 years old. One patient had been previously treated with (standard schedule) high-dose IL-2 several years before enrollment. Prior VEGFR-TKI treatment and progression were allowed, but actually none enrolled, so all the Dose delivery for the planned up to 12 doses of pembrolizumab had a median of 12 doses – 14 subjects missed none -- and average of 9.9 doses; for IL-2 planned up to 40 doses there was a median 25 doses and average 22.6, counting as 0 those courses in which the subject was not still on study or the subject was not even admitted.

As detailed in Table 2, five patients (19%) had a complete response to therapy, and fourteen patients (52%) had a partial response, yielding an objective response rate of 70% (95% CI: 0.50-0.86), exceeding the response requirements to successfully reject the null hypothesis. Nine patients responded after pembrolizumab monotherapy was delivered in block one. Eight of these patients went on to receive high-dose IL-2, and one patient had very good disease response after monotherapy and declined to proceed with the administration of high-dose IL-2 due to other personal circumstances. Ten additional patients responded after treatment with the combination of IL-2 and pembrolizumab (nine patients after block two and one patient responded after block three).
The objective response rate for patients receiving at least four doses of pembrolizumab and one dose of IL-2 was 77% (17/22, 95% CI: 0.54-0.91), and the objective response rate for patients receiving at least six doses of pembrolizumab plus at least twenty doses of IL-2 was 82% (14/17, 95% CI: 0.56-0.95). In addition, all patients in our study were alive at one year. While a formal comparison against matched controls in the PROCLAIM database was not carried out, the combination of 5-in-a-row high-dose IL-2 and pembrolizumab has a higher rate that appears to compare favorably to usual-14-in-a-row high-dose IL-2 alone.

The Kaplan-Meier estimate for progression free survival at 12 months was 63% (95% confidence interval 42% to 78%). Kaplan-Meier estimates for overall survival and progression-free survival are detailed in Figures 2 and 3, respectively.

As detailed in Figure 4, nine patients (including one patient who received only pembrolizumab) continue without any further cancer-specific treatment for progression as of data cut-off, with a minimum follow-up of 23 months and a median follow-up of 27 months. Of the patients who have thus far progressed, six (one with prior brain disease that was treated) progressed via the development of new brain metastases, making this the most common new site of progression. The latencies of the brain metastases detection, counting from start of treatment, were 182, 195, 211, 218, 293 and 793 days (indicated by the letter B in the figure).

Treatment-related adverse events are detailed in Table 3. No grade 5 events occurred. The most common grade 3 or 4 treatment-related events were decreased urinary output (37%), lymphopenia (26%), hypotension (33%), and hypophosphatemia (26%), all common in patients receiving various schedules of high dose IL-2.2,4-6,37-39 A formal cross-trial comparison of event-frequencies was not conducted.
Discussion

The primary objective of the study was met, as the response rate significantly exceeded that required to reject the null hypothesis. Notably, there was a relatively high rate (19%) of complete responses, and relatively high overall response rate (70%). As a point of reference, larger 14-in-a-row (standard, current label) schedule for high dose IL-2 had had randomized trial response rates of 23.2% (5) 25% (5b), 15% (2); and retrospective data set 15% (4); differences of patient selection among these, and versus the present series are definitely acknowledged, although the intent for the present series was to have a “usual IL-2” type of patient selection. The objective response rate of 70% reported in the present study with the 5-in-a-row IL-2 schedule compares to a response rate of 24.5% in favorable risk patients treated with (mostly) standard schedule high-dose IL-2 alone as per the PROCLAIM registry, 26.0% in intermediate risk patients treated with high-dose IL-2 alone, and 17.2% in poor risk patients treated with high dose IL-2 alone.³⁶

One significant benefit of the treatment regimen was that a number of patients obtained long, unmaintained treatment-free intervals following study therapy, which is an outcome of increasing interest in cancer care.⁴⁰ In addition, the treatment met the pre-specified safety endpoints. These data did not show any large increase in autoimmune events with the combination of the two therapies. It is acknowledged that once the two-part portion of the treatment started, attribution of any particular adverse event to one or the other of the medications could not be made definitively. The adverse events that were observed appear to be consistent with the known side effect profile of the two medications.

Notably, there was a higher than anticipated incidence of brain metastases in the study population, but this finding may be due to the relatively small number of patients studied. At
least two patients had regression of pulmonary lesions concurrently with progression in the brain, potentially indicating a difference in the anti-tumor effects of the treatment for brain metastases as compared to other sites of disease. The latencies from treatment start to identification of the brain lesions were at a minimum of 6 months, but not clustered at a point after pembrolizumab had stopped. While the efficacy of IL-2 in the treatment of brain metastases from clear cell renal cancer is not well-defined, anti-PD-1 therapy has been shown to have limited efficacy for central nervous system metastases from mCCRC. In practice, the treatment for brain metastases is primarily via surgery or radiation rather than systemic therapy.

The limitations of our study include the fact that it is a single arm, single institutional experience, and as such the generalizability of the results may be limited. In addition, rates of severe toxicity related to IL-2 may be lower at high-volume centers. Further, the specific contribution of IL-2 to the response rate, or to the durability of response, particularly in those patients who had a response easily demonstrated after the first block of pembrolizumab monotherapy, remains undefined. While the response rate in our study was significant, other combinations such as axitinib and avelumab (51.4%), axitinib and pembrolizumab (59.3%), cabozantinib and nivolumab (55.7%), and lenvatinib and pembrolizumab (71.0%) also have impressive response rates, with eligibility criteria that were less strict and did not require dedicated cardiac or pulmonary function testing prior enrollment. Notably, however, no patients were excluded due to these screening evaluations in our study.

Conclusion

This study has demonstrated the feasibility and potential efficacy of combining high dose IL-2 and pembrolizumab in patients with mCCRC, potentially adding IL-2 to the list of suitable partners for anti-PD-1/L1 therapy in the treatment of this disease. A direct efficacy and toxicity
comparison in a prospective, randomized multicenter format would serve to confirm this experience. The observed tolerability, response rate, and frequency of unmaintained durable response are encouraging. Other combinations, such as that of nivolumab with pegylated IL-2 formulations (NKTR, bempegaldesleukin), and ALKS-4230 IL-2/ILRalpha combination, continue to be subjects of active investigation.\textsuperscript{21,44} Whereas aldesleukin has a half-life of between 13 and 85 minutes, bempegaldesleukin has is a pegylated prodrug that gradually generates an active cytokine that preferentially binds to IL2Rβγ, thus minimizing stimulation of IL2Rαβγ and T regulatory compartment.\textsuperscript{45} As such, the specific immune changes and subsequently the anti-tumor effect of these two compounds may differ in practice. As additional effective combinations are found, ideal sequencing is another area of interest.\textsuperscript{46} While our study evaluated the role of IL-2 and pembrolizumab in the first line, there may potentially be a role for this therapy as a salvage regimen following progression on PD-1 or on VEGF type treatments. In addition, whereas IL-2 is best studied in melanoma and in renal cancer, pembrolizumab is utilized in a wide variety of different tumor types and has efficacy in tumors of all types with microsatellite instability-high or mismatch repair deficient status.\textsuperscript{4,47} IL-2 may therefore represent a partner agent that could be tested for a capacity to boost the durable response rate of pembrolizumab in a variety of tumor types. An analysis of laboratory and clinical factors correlated to treatment with pembrolizumab, interleukin-2 and response will be reported separately.

**Clinical Practice Points**

IL-2 has a single-agent response rate of 15-20% and a durable complete response rate of 5-7%.

A single-agent response rate of 36% has been reported for the PD-1 inhibitor pembrolizumab.
There may be important synergies between these therapies, as cells which bear receptors for IL-2 stimulation may also be modulated by checkpoint inhibition, either directly or indirectly.

The present single arm, single-institution study evaluated the combination of these two agents in patients with metastatic clear cell renal cancer.

Subjects were treated with four nine-week blocks of therapy, receiving pembrolizumab every three weeks in all blocks and receiving four courses of high dose IL-2 in each of blocks two and three.

Nineteen out of twenty-seven patients responded to therapy, including nine patients who responded after pembrolizumab alone and ten patients who responded after the addition of IL-2.

No accrual stop for safety was triggered.

The combination of pembrolizumab and IL-2 is a safe, feasible, and potentially effective therapy for metastatic clear cell renal cancer.

Acknowledgments

Special thanks to the participating patients and their families. We thank Michael Holman, (Prometheus) for his advocacy for the project at its early stages. Financial support by contract with Clinigen, Inc. Pembrolizumab furnished by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. IND and regulatory support through Moffitt Cancer Center.

REFERENCES

1. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. *Immunity*. 2010;33:153-165.
2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. *The cancer journal from Scientific American*. 2000;6:555-57.
3. Lee S, Margolin K. Cytokines in cancer immunotherapy. *Cancers*. 2011;3:3856-3893.
4. Alva A, Daniels GA, Wong MK, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. *Cancer Immunology, Immunotherapy*. 2016;65:1533-1544.
5. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. *Journal of clinical oncology.* 2009;23:133-141.

6. McDermott DF, Cheng SC, Signoretti S et al. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. *Clin Cancer Res.* 2015 Feb 1;21(3):561-8.

7. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. *The Lancet Oncology.* 2019;20:1370-1385.

8. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. *Cancer journal (Sudbury, Mass.).* 2014;20:265.

9. Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. *Cancer Immunology, Immunotherapy.* 2017;66:551-564.

10. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Frontiers in pharmacology.* 2017;8:561.

11. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *New England Journal of Medicine.* 2015;373:1803-1813.

12. McDermott DF, Lee J-L, Szczylik C, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427: American Society of Clinical Oncology; 2018.

13. Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. *Frontiers in oncology.* 2018;8:86.

14. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *New England Journal of Medicine.* 2019;380:1103-1115.

15. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *New England Journal of Medicine.* 2019;380:1116-1127.

16. Schmid TA, Gore ME. Sunitinib in the treatment of metastatic renal cell carcinoma. *Therapeutic advances in urology.* 2016;8:348-371.

17. Turajlic S, Larkin J, Swanton C. SnapShot: renal cell carcinoma. *Cell.* 2015;163:1556-1556. e1551.

18. Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal Cell Carcinoma. *New England Journal of Medicine.* 2021;384:829-841.

19. Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. *New England Journal of Medicine.* 2021;384:1289-1300.

20. Aggen DH, Drake CG, Rini BI. Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer-Combination Therapy in the First Line Setting. *Clinical Cancer Research.* 2020.

21. Diab A, Hurwitz ME, Cho DC, et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

22. Keytruda (pembrolizumab) injection label. Vol 2020.

23. Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network.* 2019;17:255-289.

24. Waters RS, Perry JS, Han S, Bielekova B, Gedeon T. The effects of interleukin-2 on immune response regulation. *Mathematical medicine and biology: a journal of the IMA.* 2018;35:79-119.

25. Carter LL, Fouser LA, Jussif J, et al. PD-1: PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. *European journal of immunology.* 2002;32:634-643.

26. Chikuma S, Terawaki S, Hayashi T, et al. PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. *The Journal of Immunology.* 2009;182:6682-6689.
27. Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. *Clinical Cancer Research.* 2016;22:5461-5471.

28. Buchbinder EJ, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. *Journal for Immunotherapy of Cancer.* 2019;7:49.

29. Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. *Journal of Immunotherapy.* 2014;37:187-191.

30. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—Update and clarification: From the RECIST committee. *European journal of cancer.* 2016;62:132-137.

31. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *American journal of clinical oncology.* 1982;5:649-656.

32. Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. *Biometrics.* 2005;61:540-545.

33. Finkelstein SE, Carey T, Fricke I, et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. *Journal of immunotherapy.* 2010;33:817-827.

34. Simon R. Optimal two-stage designs for phase II clinical trials. *Controlled clinical trials.* 1989;10:1-10.

35. Wilson EB. Probable inference, the law of succession, and statistical inference. *Journal of the American Statistical Association.* 1927;22:209-212.

36. Fishman M, Dutcher J, Clark J, et al. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM SM registry. *Journal for Immunotherapy of Cancer.* 2019;7:1-7.

37. Thompson JA, Lee DJ, Cox WW, et al. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. *Cancer research.* 1987;47:4202-4207.

38. Webb D, Belldegrun A, Vaughan E, Linehan W, Rosenberg S. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. *Clinical nephrology.* 1988;30:141-145.

39. Schwartz RN, Stover L, Dutcher JP. Managing toxicities of high-dose interleukin-2. *Oncology (Williston Park, NY).* 2002;16:11-20.

40. Regan MM, Werner L, Rao S, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma. *Journal of Clinical Oncology.* 2019;37:3350-3358.

41. Flippot R, Dalban C, Laguerre B, et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. *Journal of Clinical Oncology.* 2019;37:2008-2016.

42. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.20192019.

43. Mehta K, Appleman L, Wang H, Tarhini AA, Parikh RA. Annual hospital volume of high dose interleukin-2 and inpatient mortality in melanoma and renal cell carcinoma patients. *PloS one.* 2016;11:e0147153.

44. Powderly J, Carthon B, Ernstoff M, et al. ARTISTRY-2: a phase 1/2 study of subcutaneously administered ALKS 4230 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. *Journal for Immunotherapy of Cancer.* Vol 7: BMC CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND; 2019.

45. Bentebibel S-E, Hurwitz ME, Bernatchez C, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rγc-biased cytokine, in patients with advanced or metastatic solid tumors. *Cancer discovery.* 2019;9:711-721.
46. Zhang T, Ballman KV, Choudhury AD, et al. PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704): American Society of Clinical Oncology; 2019.

47. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clinical Cancer Research.* 2019;25:3753-3758.

Table 1. Demographics and disease characteristics at baseline (N=27)

| Characteristic                     | Value  |
|------------------------------------|--------|
| Age                                | 60     |
| <65 yr - number (%)                | 17 (63)|
| Male sex - number (%)              | 22 (81)|
| IMDC prognostic risk - number (%)  |        |
| Favorable                          | 10 (37)|
| Intermediate                       | 16 (59)|
Table 2. Summary of objective responses

| Objective response rate - number (%) | 19 (70) |
|-------------------------------------|---------|
| Best objective response - number (%)|         |
| Complete Response                   | 5 (19)  |
| Partial Response                    | 14 (52) |
| Stable disease                      | 5 (19)  |
| Progressive disease                 | 2 (7)   |
| Not Assessed                        | 1 (4)*  |

* One patient did not receive any study treatment after baseline imaging was obtained
Table 3. Adverse events which are at least possibly treatment-related and which occurred in >10% of patients (N=27)

| Adverse Event – number (%) | Number of Patients (Percent) |
|----------------------------|-----------------------------|
|                            | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total |
| Decreased Urinary Output   | 1 (4%)  | 0 (0%)  | 9 (33%) | 1 (4%)  | 0 (0%)  | 11 (41%) |
| Hypotension                | 0 (0%)  | 0 (0%)  | 8 (30%) | 1 (4%)  | 0 (0%)  | 9 (33%)  |
| Sinus tachycardia          | 4 (15%) | 2 (7%)  | 2 (7%)  | 0 (0%)  | 0 (0%)  | 8 (30%)  |
| Lymphocyte count decreased | 0 (0%)  | 0 (0%)  | 0 (0%)  | 7 (26%) | 0 (0%)  | 7 (26%)  |
| Creatinine increased       | 0 (0%)  | 3 (11%) | 4 (15%) | 0 (0%)  | 0 (0%)  | 7 (26%)  |
| Hypophosphatemia           | 0 (0%)  | 0 (0%)  | 7 (26%) | 0 (0%)  | 0 (0%)  | 7 (26%)  |
| Leukocytosis               | 0 (0%)  | 0 (0%)  | 6 (22%) | 0 (0%)  | 0 (0%)  | 6 (22%)  |
| Acute kidney injury        | 1 (4%)  | 1 (4%)  | 3 (11%) | 1 (4%)  | 0 (0%)  | 6 (22%)  |
| Rash maculo-papular        | 3 (11%) | 2 (7%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 5 (19%)  |
| Hyponatremia               | 1 (4%)  | 0 (0%)  | 4 (15%) | 0 (0%)  | 0 (0%)  | 5 (19%)  |
| Blood bilirubin increased  | 0 (0%)  | 0 (0%)  | 4 (15%) | 0 (0%)  | 0 (0%)  | 4 (15%)  |
| Dyspnea                    | 1 (4%)  | 1 (4%)  | 1 (4%)  | 1 (4%)  | 0 (0%)  | 4 (15%)  |
| Arthralgia                 | 0 (0%)  | 1 (4%)  | 3 (11%) | 0 (0%)  | 0 (0%)  | 4 (15%)  |
| Atrial fibrillation        | 0 (0%)  | 1 (4%)  | 3 (11%) | 0 (0%)  | 0 (0%)  | 4 (15%)  |
| Capillary leak syndrome    | 0 (0%)  | 1 (4%)  | 1 (4%)  | 1 (4%)  | 0 (0%)  | 3 (11%)  |
| Dry skin                   | 2 (7%)  | 1 (4%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 3 (11%)  |
| Pruritus                   | 3 (11%) | 0 (0%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 3 (11%)  |
| Fatigue                    | 1 (4%)  | 1 (4%)  | 1 (4%)  | 0 (0%)  | 0 (0%)  | 3 (11%)  |
| Fever                      | 2 (7%)  | 1 (4%)  | 0 (0%)  | 0 (0%)  | 0 (0%)  | 3 (11%)  |
Figure 1. Protocol schema

**if CR after first 3 pembrolizumab, consider pembrolizumab monotherapy**

- **P** = pembrolizumab
- **IS** = IL-2, 5-in-a-row
- PD = progression of disease
- SD+ = stable disease, partial response, or complete response
- CT = abbreviation for CT scan or other disease assessment, such as MRI
Figure 2. Overall survival with 95% confidence interval detailed
Figure 3. Progression free survival with 95% confidence interval detailed
Figure 4. Time on treatment, subsequent survival off treatment, and overall survival

Legend: Vertical striping: Time on combination pembrolizumab and IL-2. Thin horizontal line: Time on no treatment, and without any other medical therapy. Diagonal fill: Time on no medical treatment, but after a local therapy after study treatment. Letters indicate timing and type of initial post-study treatment: B: Brain metastasis treated with radiation or (B*) surgery and radiation, L: Local resection (one renal radiofrequency ablation, one adrenal resection), X: Local treatment (mediastinal lymph node radiation therapy), M: Start of other medical therapy.